Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bone Biologics (BBLG) EPS (Weighted Average and Diluted) (2016 - 2025)

Bone Biologics has reported EPS (Weighted Average and Diluted) over the past 2 years, most recently at $0.25 for Q2 2017.

  • Quarterly EPS (Weighted Average and Diluted) rose 292.31% to $0.25 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was -$2.66 through Jun 2017, changed N/A year-over-year, with the annual reading at -$2.65 for FY2025, 90.85% up from the prior year.
  • EPS (Weighted Average and Diluted) was $0.25 for Q2 2017 at Bone Biologics, up from -$0.13 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.25 in Q2 2017 and troughed at -$0.13 in Q2 2016.